A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC). The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with other therapies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci z potwierdzonym, zaawansowanym nowotworem, którego nie można leczyć standardowymi metodami.
- •Dostępna próbka guza (jeśli bezpieczne i możliwe).
- •Pacjent musi wyrazić zgodę na pobranie próbki guza (biopsję), jeśli jest to bezpieczne i możliwe.
- •Choroba widoczna w badaniach obrazowych.
- •Ogólny stan zdrowia pozwalający na udział w badaniu.
- •Przewidywany czas życia co najmniej 12 tygodni.
- •Prawidłowa funkcja serca.
- •Dobra ogólna czynność narządów.
✗ Disqualifies
- •Pacjenci, którzy wcześniej nie byli leczeni określonymi terapiami (zależnie od grupy badanej).
- •Pacjenci z pewnymi zmianami genetycznymi w guzie (zależnie od grupy badanej).
- •Pacjenci z określonym typem niestabilności mikrosatelitarnej guza (zależnie od grupy badanej).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (54)
UCSD
La Jolla, United States
USC Norris Comprehensive Cancer Center
Los Angeles, United States
Sharp Healthcare
San Diego, United States
Rocky Mountain Cancer Centers
Lone Tree, United States
Florida Cancer Specialists
Fort Myers, United States
University of Florida
Gainesville, United States
Sarah Cannon Research Institute (Lake Nona)
Orlando, United States
Emory University
Atlanta, United States
Massachusetts General Hospital - Dana Farber
Boston, United States
Karmanos Cancer Institute
Detroit, United States
SSM Health Saint Louis University Hospital
St Louis, United States
Washington University School of Medicine at St Louis
St Louis, United States
Cayuga Medical Center
Ithaca, United States
Mt. Sinai
New York, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Hematology-Oncology Associates of Central New York
Syracuse, United States
Cleveland Clinic
Cleveland, United States
Ohio State University
Columbus, United States
Taylor Cancer Research Center
Maumee, United States
SSM OKC Hightower Clinical
Oklahoma City, United States
University of Pennsylvania
Philadelphia, United States
The University Of Tennessee Health Science Center
Memphis, United States
Sarah Cannon Research Institute
Nashville, United States
Texas Oncology
Dallas, United States
Oncology Consultants
Houston, United States
Texas Oncology
Tyler, United States
Utah Cancer Specialists
Salt Lake City, United States
University of Utah Health Huntsman Cancer Hospital
Salt Lake City, United States
Oncology & Hematology Associates of Southwest Virginia
Roanoke, United States
Georgetown University Medical Center
Georgetown, United States
Cancer Care Northwest
Spokane, United States
Cliniques universitaires Saint-Luc
Brussels, Belgium
Institut Jules Bordet
Brussels, Belgium
UZ Gent
Ghent, Belgium
Chu Ucl Namur Site De Sainte-Elisabeth
Namur, Belgium
Hopital Saint Andre, CHU Bordeaux
Bordeaux, France
Centre Leon Berard
Lyon, France
Hopital La Timone
Marseille, France
Institut Régional du Cancer de Montpellier
Montpellier, France
Centre Antoine Lacassagne
Nice, France
Institut Curie
Paris, France
Institut Gustave Roussy
Paris, France
Centre Henri Becquerel
Rouen, France
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
NKI - Antoni van Leeuwenhoek
Amsterdam, Netherlands
UMC Radboud
Nijmegen, Netherlands
UMC Utrecht
Utrecht, Netherlands
Vall d'Hebron
Barcelona, Spain
Hospital 12 de Octubre
Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Hospital Universitario de Navarra
Pamplona, Spain
Instituto Valenciano de Oncologia
Valencia, Spain
Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
Sarah Cannon Research Institute
London, United Kingdom
Trial contact
Silke Thiele, MD
Eduardo Pennella, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/31/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.